MMJ Group Holdings Ltd

MMJ PhytoTech Ltd (ASX:MMJ) advises that it has executed a binding Term Sheet with Canadian-based Harvest One Capital Corp. for the sale to Harvest One of 100% of the issued shares of United Greeneries Holdings Ltd and Satipharm AG respectively.

MMJ PhytoTech Ltd (ASX:MMJ) is pleased to provide its quarterly activities report for the period ended 30 September 2016.

MMJ PhytoTech Ltd (ASX:MMJ) is pleased to provide the company's Annual Report to shareholders.

MMJ PhytoTech Limited (ASX:MMJ) has raised A$4 million through the placement of 19,512,196 fully paid ordinary shares ("Placement") to institutional and sophisticated investors at $0.205 per share.

MMJ PhytoTech Ltd (ASX:MMJ) Directors present their report on the Consolidated Entity ("Group") consisting of MMJ PhytoTech Limited ("MMJ" or the "Company") (formerly PhytoTech Medical Ltd) and the entities it controlled at the end of, or during, the year ended 30 June 2016.

MMJ PhytoTech Ltd (ASX:MMJ) is pleased to provide the latest Investor Presentation regarding MMJ Brands to List on TSX-V via RTO.

MMJ PhytoTech Ltd (ASX:MMJ) is pleased to provide the latest Investor Presentation regarding MMJ Brands to List on TSX-V via RTO.

MMJ PhytoTech Ltd (ASX:MMJ) is pleased to advise that it is set to unlock significant value for shareholders through the spin out of its core cannabis subsidiaries, United Greeneries Holdings Ltd and Satipharm AG, on the TSX-V.

MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that its wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Limited ("PTL"), will commence a Phase 2 clinical study into the efficacy of the its PTL101 capsules in treating intractable epilepsy in children.

MMJ PhytoTech Limited (ASX:MMJ) ("MMJ" or "the Company") is pleased to advise that Catherine Harvey has been appointed as Chief Operations Officer, effective 1 September 2016.